The investment will support the transition of the company’s biomaterial products from pre-clinical studies to clinical trials.
Spiderwort’s biomaterials, which hve received a breakthrough device designation by the FDA, use plant-derived scaffolding to create a structure for tissue to grow. The company is developing two core products:
– CelluBridge is a cellulose-based biomaterial that promotes the repair and regeneration of the spinal cord
– CelluJuve is a cellulose-based dermal filler designed to address different patient use cases including injury recovery and cosmetic enhancement
“The results in the lab are very encouraging,” Andrew Pelling, PhD, chief scientific officer at Spiderwort, said in the news release. “Spiderwort was founded on asking big questions and taking big risks and that work is now paying off. We’re looking forward to moving our innovations to the clinic and improving the quality of life of people around the world.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
